Provided by Tiger Trade Technology Pte. Ltd.

EVEREST MED

30.140
+2.1607.72%
Volume:9.34M
Turnover:277.40M
Market Cap:10.67B
PE:-33.87
High:30.480
Open:28.020
Low:28.020
Close:27.980
52wk High:58.600
52wk Low:22.700
Shares:354.00M
HK Float Shares:354.00M
Volume Ratio:2.31
T/O Rate:2.64%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.890
ROE:-1.18%
ROA:-1.06%
PB:1.75
PE(LYR):-33.87
PS:3.79

Loading ...

Everest Medicines Announces Mainland China Commercialization Deal with Hainan Herui for Budesonide Enteric Capsules

Bulletin Express
·
Jun 24

Everest Medicines - Enters Commercialization Collaboration With Hainan Herui Pharmaceutical for Budesonide Capsules

THOMSON REUTERS
·
Jun 24

Everest Medicines enters China commercialization collaboration with Hainan Herui for budesonide enteric capsules

Reuters
·
Jun 24

Everest Medicines' Substantial Shareholder Boosts Stake

MT Newswires Live
·
Jun 18

Hong Kong Market Announcement Highlights: Three IPOs Launch Including Optical Module Supplier, Lenovo Plans $2 Billion Convertible Bond Issue

Stock News
·
Jun 18

Major Shareholder Increases Stake in Everest Med

Stock News
·
Jun 18

Everest Medicines: CBC Group Adds 712,000 Shares for HK$19.20 Million, Lifting Accumulated Insider Buying to HK$172.50 Million

Bulletin Express
·
Jun 18

Everest Medicines - Cbc Group Purchases 712,000 Everest Medicines Shares for HK$19.2 Mln From 16 to 17 June

THOMSON REUTERS
·
Jun 18

Everest Medicines says CBC Group buys 712,000 shares for HK$19.2 million

Reuters
·
Jun 18

Everest Medicines shareholders approve share purchase agreement at EGM, 76.14% in favor

Reuters
·
Jun 17

Everest MED Shares Surge in Morning Trading Following Acquisition of Multi-Country Rights for Inhibitor DMX-200

Stock News
·
Jun 17

EVEREST MED Secures Exclusive Asian Rights to Promising FSGS Treatment Candidate DMX-200

Stock News
·
Jun 16

BUZZ-Australia's Dimerix soars on commercialisation deal with Everest Medicines

Reuters
·
Jun 16

Dimerix Ltd - Dimerix Licenses Dmx200 to Everest for China and Asia Region

THOMSON REUTERS
·
Jun 16

Everest Medicines signs exclusive licensing deal with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia

Bulletin Express
·
Jun 16

EVEREST MED Secures Exclusive Rights for DMX-200 Development and Commercialization in Key Asian Markets

Stock News
·
Jun 16

Everest Medicines - Agreement With Dimerix to Develop & Commercialize Dmx-200 in Greater China, South Korea and Southeast Asia

THOMSON REUTERS
·
Jun 16

Everest Medicines - Deal Includes $10 Mln Upfront, up to $30 Mln Development Milestones, $300 Mln Sales Milestones, 10%-15% Royalties

THOMSON REUTERS
·
Jun 16

Everest Medicines - Dmx-200 Receives Orphan Drug Designations From FDA and Ema

THOMSON REUTERS
·
Jun 16

Everest Medicines licenses Dimerix’s DMX-200 rights for Greater China, South Korea and Southeast Asia in deal worth up to USD 340 million

Reuters
·
Jun 16